The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

Half of the states without coverage said they are considering adding them or evaluating their coverage, it said ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to ...

Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Maggie Lilly is creating a buzz with her Party of Hive granola.

Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

The National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will rule ...